Saubio.com

NEW YORK, Feb. 27, 2021 /PRNewswire/ — Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Reinvent Technology Partners (“RTP” or the “Company”) (RTP) relating to its proposed … Read more

KURUME, Japan, Feb. 26, 2021 /PRNewswire/ — FCC Horiuchi Co., Ltd. based in Kurume City, Fukuoka Prefecture, western Japan, has conducted an experiment in inhibiting binding between ACE2 and virus spike protein using HORIUCHI L-FUCOIDAN, manufactured by the company, in collaboration with a graduate school of Kyushu University (Associate Professor Kuniyoshi Shimizu of Division of … Read more

PARIS and CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) — Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe … Read more

CAMBRIDGE, United Kingdom, Feb. 26, 2021 (GLOBE NEWSWIRE) — Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam” or the “Company”), a global leader in the supply of life science research tools, will report its Interim Results for the six-month period ended 31 December 2020 at 12.00 p.m. GMT (7.00 a.m. EST) on Monday, March 8, 2021. … Read more

NEW YORK and LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced that an interview with its CEO, Dr Kunwar Shailubhai, will air on The RedChip Money Report on Bloomberg Television on Saturday, February 27, 2021 … Read more

Highlights GAAP net loss attributable to shareholders of Teekay of $19.4 million, or $0.19 per share, and adjusted net income attributable to shareholders of Teekay(1) of $2.8 million, or $0.03 per share, in the fourth quarter of 2020 (excluding items listed in Appendix A to this release). Total adjusted EBITDA(1) of $201.1 million in the … Read more

LOS ANGELES, Feb. 25, 2021 /PRNewswire/ — In recognition of his proficiency in federal, state and local election, campaign and government law, Kaufman Legal Group today announced that it has elevated George Yin to Shareholder. “George is distinguished and admired in the political and legal communities as a leader in the field,” said Stephen J. Kaufman, Managing Shareholder … Read more

VANCOUVER, BC, Feb. 25, 2021 /CNW/ – Reconnaissance Energy Africa Ltd. (the “Company” or “ReconAfrica”) (TSXV: RECO) (OTCQX: RECAF) (Frankfurt: 0XD) is pleased to both provide an update on drilling operations in the Kavango sedimentary basin in the Kalahari Desert of North East Namibia and announce that it has qualified as the Canadian TSX Venture … Read more

Genus plc (LSE: GNS), a global biotechnology leader in animal genetics, today reported interim results for the six-months period ending December 31, 2020, as well as provided a business update on recent corporate developments in its worldwide porcine and bovine genetics businesses. The full report has been made available on the Investors section of the … Read more

OSLO, Norway, Feb. 24, 2021 /PRNewswire/ — Record quarterly revenue of $27.9 million, reflecting growth of 78% over Q4 2019 Gross margin increased to 44% in Q4, from 43% in Q4 2019 Record quarterly EBITDA adjusted of $6.9 million in Q4 2020, compared with $2.6 million in Q4 2019 Announced two acquisitions strengthening the Gaming … Read more

PLYMOUTH MEETING, Pa. and GERMANTOWN, Md. and HILDEN, Germany, Feb. 24, 2021 /PRNewswire/ — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO’s therapies. … Read more

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO’s therapies. (*Complementary when referring to the US regulatory pathway.) The initial project in this … Read more